Athersys Inc (ATHX) – Strategy, SWOT and Corporate Finance Report

Athersys Inc (ATHX) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Athersys Inc (Athersys) is a biotechnology company that discovers and develops novel and proprietary therapies in the field of regenerative medicine. It is investigating its lead platform, MultiStem, a patented stem cell product for treating chronic conditions such as cardiovascular diseases, inflammatory and immune disorders, neurological, and pulmonary disorders. The company’s MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, traumatic brain injury, vascular disease, acute pulmonary distress, wound healing, organ reperfusion, bone marrow/hematopoietic stem cell transplantation, ischemic stroke, and autoimmune disease. The company's pipeline consists of therapeutic product development programs in multiple disease areas, through the application of proprietary technologies. Athersys is headquartered in Cleveland, Ohio, the US.

Scope

• Detailed information on Athersys Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Athersys Inc in the form of a SWOT analysis

• An in-depth view of the business model of Athersys Inc including a breakdown and examination of key business segments

• News about Athersys Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Athersys Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Athersys Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Athersys Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Plus Therapeutics Inc

SanBio Inc

Pfizer Inc

Pluri Inc

Lisata Therapeutics Inc

Caladrius Biosciences, 18301 Von Karma Ave., Suite 130, Irvine, California, United States

Arena Pharmaceuticals Inc

Plus Therapeutics Inc

SanBio Inc

Pfizer Inc

Pluri Inc

Vericel Corp

Cryo-Cell International Inc

Vericel Corp

Cryo-Cell International Inc

Arena Pharmaceuticals Inc

Caladrius Biosciences Inc

Mesoblast Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Athersys Inc - Key Facts

Athersys Inc - Key Employees

Athersys Inc - Key Employee Biographies

Athersys Inc - Major Products and Services

Athersys Inc - History

Athersys Inc - Company Statement

Athersys Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Athersys Inc - Business Description

Business Segment: Contract Revenue

Performance

Business Segment: Grant Revenue

Performance

R&D Overview

Athersys Inc - Corporate Strategy

Athersys Inc - SWOT Analysis

SWOT Analysis - Overview

Athersys Inc - Strengths

Athersys Inc - Weaknesses

Athersys Inc - Opportunities

Athersys Inc - Threats

Athersys Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Athersys Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jan 30, 2023: Athersys top participate in International Stroke Conference and BioProcess International

Jan 05, 2023: Athersys Appoints Joseph Nolan to Its Board of Directors

Nov 15, 2022: Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 11, 2022: Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference

Aug 11, 2022: Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

Jun 21, 2022: Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

Jun 09, 2022: Athersys Postpones Annual Meeting of Stockholders

Jun 02, 2022: Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs

May 06, 2022: Athersys Reports First Quarter 2022 Results

Apr 01, 2022: Athersys to Participate in Two Upcoming Investor Conferences

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Athersys Inc, Key Facts

Athersys Inc, Key Employees

Athersys Inc, Key Employee Biographies

Athersys Inc, Major Products and Services

Athersys Inc, History

Athersys Inc, Subsidiaries

Athersys Inc, Key Competitors

Athersys Inc, Ratios based on current share price

Athersys Inc, Annual Ratios

Athersys Inc, Annual Ratios (Cont…1)

Athersys Inc, Interim Ratios

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Athersys Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Athersys Inc, Performance Chart (2018 – 2022)

Athersys Inc, Ratio Charts

Athersys Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Athersys Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports